Tuesday, March 3, 2020

Vaccines Market to Witness Robust Expansion Throughout the Forecast Period 2019–2030 - Pfizer, GlaxoSmithKline, Merck & Co

Vaccines are biological preparations which are used to boost immunity by activating acquired immunity against a particular disease. Vaccines typically constitutes of agents resembling a disease-causing microorganism. It is fabricated from either a weakened or killed form of the microbe, its surface protein or toxins. The process of administration of vaccine is known as vaccination. The vaccination agent assists the body in recognizing the agent as a threat and destroys it. Moreover, it helps the body to recognize and destroy any microorganism associated with the agent for future encounters.

Market Industry Reports (MIR) has published a new report titled "Vaccines Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global vaccines market is expected to be valued at US$ 36,297.2 Million in 2019 and is anticipated to grow at a CAGR of 6.0% from 2019 to 2030.

Major Key Players of the Vaccines Market are:
Pfizer, GlaxoSmithKline, Merck & Co., Sanofi Pasteur Limited (Sanofi), AstraZeneca, CSL Limited, Bavarian Nordic, Panacea Biotec Limited, PT Bio Farma (Persero) and Serum Institute of India Pvt. Ltd. among others

Read More @ http://www.sbwire.com/press-releases/vaccines-market-to-witness-robust-expansion-throughout-the-forecast-period-2019-2030-pfizer-glaxosmithkline-merck-co-1280145.htm 


The growth of the vaccines market can be attributed to factors such as rising incidences of infectious diseases, namely malaria, ebola and influenza among others. Moreover, growing immunization drives worldwide conducted by several government and non-government establishments to spread awareness about diseases have been vital in contributing to the extensive growth if this market. Similarly, market players in association with various universities are conducting research to develop vaccine. For instance in September 2018, Johnson & Johnson announced the collaboration between Coalition for Epidemic Preparedness Innovations (CEPI) & Jenner Institute, University of Oxford and Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration was aimed to develop and manufacture vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV). However, high developmental costs and requirement of specialized monitoring devices and equipment which further incurs costs is anticipate to impede the growth of the market in the coming years.

Rising prevalence and incidences of infectious diseases have been a major factor contributing to the extensive adoption of vaccines worldwide. Infectious diseases, more often considered to be a global crisis, is estimated to kill 17 million people every year. It is further estimated that nearly 50,000 women, men and children die every day of infectious disease which otherwise could be cured or prevented. Increasing burden of these diseases significantly affects the socioeconomic development of nations by crippling the prospects of better future.


No comments:

Post a Comment